GW Henssler & Associates Ltd. Decreases Stock Holdings in Amgen Inc. $AMGN

Key Points

• GW Henssler & Associates Ltd. has decreased its stake in Amgen Inc. by 33.8%, now holding 59,844 shares valued at approximately $18.64 million.
• Amgen reported strong quarterly earnings with a $6.02 EPS, surpassing analyst estimates of $5.28, and noted a 9.4% year-over-year revenue increase to $9.18 billion.
• The company declared a quarterly dividend of $2.38 per share, providing a 3.3% dividend yield for investors.

GW Henssler & Associates Ltd. decreased its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 33.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 59,844 shares of the medical research company's stock after selling 30,579 shares during the period. GW Henssler & Associates Ltd.'s holdings in Amgen were worth $18,644,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the stock. Continuum Advisory LLC boosted its stake in shares of Amgen by 0.7% during the 4th quarter. Continuum Advisory LLC now owns 5,154 shares of the medical research company's stock valued at $1,343,000 after purchasing an additional 35 shares in the last quarter. Octavia Wealth Advisors LLC lifted its position in Amgen by 1.5% during the 1st quarter. Octavia Wealth Advisors LLC now owns 2,435 shares of the medical research company's stock valued at $759,000 after acquiring an additional 35 shares during the period. Affinity Capital Advisors LLC lifted its position in Amgen by 4.5% during the 1st quarter. Affinity Capital Advisors LLC now owns 861 shares of the medical research company's stock valued at $246,000 after acquiring an additional 37 shares during the period. Accredited Investors Inc. lifted its position in Amgen by 1.7% during the 1st quarter. Accredited Investors Inc. now owns 2,164 shares of the medical research company's stock valued at $674,000 after acquiring an additional 37 shares during the period. Finally, Rockline Wealth Management LLC lifted its holdings in shares of Amgen by 3.2% during the first quarter. Rockline Wealth Management LLC now owns 1,240 shares of the medical research company's stock valued at $386,000 after purchasing an additional 38 shares during the last quarter. Institutional investors own 76.50% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Raymond James Financial started coverage on Amgen in a research report on Wednesday. They set a "market perform" rating for the company. Mizuho upped their target price on shares of Amgen from $235.00 to $280.00 and gave the stock a "neutral" rating in a research note on Wednesday, May 7th. Erste Group Bank downgraded shares of Amgen from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 8th. UBS Group dropped their target price on shares of Amgen from $326.00 to $317.00 and set a "neutral" rating on the stock in a research note on Wednesday, August 6th. Finally, Wall Street Zen downgraded shares of Amgen from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Amgen presently has an average rating of "Hold" and a consensus price target of $304.43.

Amgen Stock Performance

Shares of AMGN traded down $3.75 during mid-day trading on Thursday, hitting $280.10. 2,620,795 shares of the company traded hands, compared to its average volume of 2,796,943. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. The stock has a 50-day moving average price of $293.70 and a two-hundred day moving average price of $292.75. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $339.17. The stock has a market cap of $150.79 billion, a price-to-earnings ratio of 22.90, a P/E/G ratio of 2.50 and a beta of 0.49.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The medical research company reported $6.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.28 by $0.74. The firm had revenue of $9.18 billion during the quarter, compared to the consensus estimate of $8.86 billion. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The company's revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $4.97 EPS. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. Equities analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 12th. Investors of record on Friday, August 22nd will be paid a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, August 22nd. This represents a $9.52 dividend on an annualized basis and a yield of 3.4%. Amgen's dividend payout ratio is presently 77.84%.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 1,267 shares of the company's stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total transaction of $376,286.33. Following the sale, the senior vice president owned 7,209 shares of the company's stock, valued at $2,141,000.91. This represents a 14.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.69% of the stock is currently owned by insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.